Clinical Pharmacokinetics Fundamental hypothesis: a relationship exists between the pharmacological or toxic response to a drug and the accessible concentration.

Slides:



Advertisements
Similar presentations
PHARMACOKINETIC MODELS
Advertisements

Instant Clinical Pharmacology E.J. Begg
First, zero, pseudo-zero order elimination Clearance
HEPATIC CLEARANCE Q x CA Q x CV Q(CA - CV) 1. Mass Balance
Clinical Pharmacokinetics
PHARMACOKINETIC.
DISPOSITION OF DRUGS The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill,
Selected bioavailability and pharmacokinetic calculations Dr. Osama A. A. Ahmed.
Pharmacokinetics of Drug Absorption
Pharmacokinetics Questions
Nonlinear pharmacokinetics
One-compartment open model: Intravenous bolus administration
Week 3 - Biopharmaceutics and Pharmacokinetics
Laplace transformation
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Week 4 - Biopharmaceutics and Pharmacokinetics
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Dose Adjustment in Renal and Hepatic Disease
Toxicokinetic Calculations
Gokaraju Rangaraju College of Pharmacy
Module 2 # 3 Pharmacokinetics how to make sense of the previous lesson or why do I have to learn this stuff?
INTRAVENOUS INFUSION.
Pharmacology Department
VM 8314 Dr. Jeff Wilcke Pharmacokinetic Modeling (describing what happens)
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
Quantitative Pharmacokinetics
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
PHARMACOKINETICS 1. Fate of drugs in the body 1.1 absorption
Pharmacokinetics Introduction
10/13/20151Prof. Mazen Qato. OBJECTIVES 10/13/2015Prof. Mazen Qato2.
Lecture 2.  Clearance Ability to eliminate the drug  Volume of distribution (Vd) The measure of the apparent space in the body available to contain.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
PHARMACOKINETIC MODELS
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
One Compartment Open Model IV bolus
The General Concepts of Pharmacokinetics and Pharmacodynamics
Multiple dosing: intravenous bolus administration
1 Single-dose kinetics Plasma [Drug] curve Upon administration [drug] plasma reaches a max Then begins to decline as the Drug is eliminated Cp max = max.
PHARMACOKINETICS INTRODUCTION
1. Fate of drugs in the body 1.1 absorption 1.2 distribution - volume of distribution 1.3 elimination - clearance 2. The half-life and its uses 3. Repeated.
Continuous intravenous infusion (one-compartment model)
PHARMACOKINETICS Definition: quantitative study of drug absorption, distribution, metabolism, and excretion (ADME), and their mathematical relationship.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.
Pharmacology Department
The General Concepts of Pharmacokinetics and Pharmacodynamics
Time Plasma Conc (hr) (mg/L) Below limit of detection 1 Compartment IV Analysis & Renal Elimination 500 mg of tobramycin.
Pharmacokinetics 2 General Pharmacology M212
Learning objectives To know what data is available from pharmacokinetic studies in man and how to handle it To know how to calculate the basic pharmacokinetic.
DOSAGE ADJUSTMENT IN RENAL AND HEPATIC DISEASES Course Title : Biopharmaceutics and Pharmacokinetics – II Course Teacher : Zara Sheikh.
INTRODUCTION TO PHARMACOKINETICS M. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague, Charles University in Prague,
MULTIPLE DOSAGE REGIMEN
Compartmental Models and Volume of Distribution
Chapter 7 COMPARTMENT MODELS
Lecture-8 Biopharmaceutics
Pharmacokinetic Modeling (describing what happens)
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Lab-3 practical pharmacology
Quantitative Pharmacokinetics
School of Pharmacy, University of Nizwa
Clinical Pharmacokinetics
Selected Bioavailability and Pharmacokinetic Calculations
1 Concentration-time curve
School of Pharmacy, University of Nizwa
Therapeutic Drug Monitoring chapter 1 part 1
Presentation transcript:

Clinical Pharmacokinetics Fundamental hypothesis: a relationship exists between the pharmacological or toxic response to a drug and the accessible concentration of the drug (e.g., in blood). Volume of distribution (V d ) Clearance (CL) Bioavailability (F) Half life

Volume of Distribution Volume of distribution (V d ) relates the amount of drug in the body to the plasma concentration of drug (C). **The apparent volume of distribution is a calculated space and does not always conform to any actual anatomic space.** note: Vd is the fluid volume the drug would have to be distributed in if Cp were representative of the drug concentration throughout the body.

DrugVd(L/70 kg body) Chlroquine13000 Warfarine9.8

Clearance (CL) Clearance is the most important property to consider when a rational regimen for long-term drug administration is designed. The clinician usually wants to maintain steady-state drug concentrations known to be within the therapeutic range.

Clearance of most drugs is constant over a range of concentrations. This means that elimination is not saturated and its rate is directly proportional to the drug concentration: this is a description of 1st-order elimination.

Capacity limited elimination (zero order)  Phenytoin, Ethanol and Aspirin

Flow dependent elimination Alprenolol Lidocaine Amitriptyline Meperidine Morphine Imipramine Propranolol Isonizide Verapamil Labetalol

CL in a given organ may be defined in terms of blood flow and [drug]. Q = blood flow to organ (volume/min) C A = arterial drug conc. (mass/volume) C V = venous drug conc. rate of elimination = (Q x C A ) - (Q x C V ) = Q (C A -C V )

Extraction Ratio Division of the previous equation by the concentration of drug that enters the given organ of elimination yields an expression for clearance of the drug by the organ: CL organ = Q(C A -C V /C A ) = Q x E E is referred to as the extraction ratio Rate of elimination = (Q x C A ) - (Q x C V ) = Q (C A -C V )

Half Life Half life is the time required to change the plasma concentration to one-half or twice of its original value

Half Life Half-life is the time taken for the concentration of drug in blood to fall by a half

Time to Steady State Time to steady state depends on half life Half life DOES NOT depend on:  Dose  Dosage Interval Tss = 4 x t ½

Time to drug accumulation and elimination

Effect of half life on plasma concentration at the beginning of dosing

Effect of half life on plasma concentration at the end of dosing

How do you change the plasma concentration? To change the plasma concentration:  Change the dose  Change the dosage interval

Bioavailability The fraction of unchanged drug reaching the systemic circulation following administration by any route.

The target concentration approaches to designing a rational dosage regimen

Maintenace Dose Dosing rate ss = Rate of elimination ss Dosing rate ss = CL X TC If the bioavailability is less than 100 percent then And if we want to give the drug intermittently: Maintenace Dose = Dosing rate x Dosing interval

Loading Dose Loading dose = V d X TC While the estimation of the amount of a loading dose may be quite correct, the rate of administration can be crucial in preventing excessive drug concentration, and slow administration of an intravenous drug (over minutes rather than seconds) is almost prudent practice

Good Luck